Your session is about to expire
← Back to Search
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Dapagliflozin for Congestive Heart Failure (DAPA-MI Trial)
Phase 3
Waitlist Available
Led By Stefan James
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
Summary
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF), cardiovascular (CV) death, and other cardiometabolic outcomes.
Eligible Conditions
- Congestive Heart Failure
- Heart Failure
- Heart Attack
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2018 Phase 4 trial • 30 Patients • NCT0300647120%
Cervicovaginal infection
13%
Urinary tract infections
100%
80%
60%
40%
20%
0%
Study treatment Arm
Dapagliflozin
Placebo
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: DapagliflozinExperimental Treatment1 Intervention
Patients will be randomized 1:1 to either dapagliflozin or placebo
Group II: PlaceboPlacebo Group1 Intervention
Placebo matching dapagliflozin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dapagliflozin
2014
Completed Phase 4
~64440
Find a Location
Who is running the clinical trial?
AstraZenecaLead Sponsor
4,388 Previous Clinical Trials
289,105,088 Total Patients Enrolled
Uppsala UniversityOTHER
507 Previous Clinical Trials
3,163,798 Total Patients Enrolled
Stefan JamesPrincipal InvestigatorUppsala University
Share this study with friends
Copy Link
Messenger